GOG 0281:  A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Please be aware that Protocol GOG-0281 will be closed to Screening on Tuesday February 13, 2018 at 5:00 PM ET. Any Screening IDs generated after 5:00 PM ET will not be assigned.

Registrations will close on April 10, 2018 (at 5:00 PM ET).

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address